Skip to content
Gold Mining News – Lifestyle
Author:
Calidi Biotherapeutics, Inc
Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711
July 8, 2026
Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit
June 24, 2026
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
June 23, 2026
Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study
June 16, 2026
Calidi Biotherapeutics Announces Investor Webinar on June 9, 2026
June 8, 2026
Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting
May 26, 2026
Calidi Biotherapeutics Provides Required NYSE American Disclosure
May 22, 2026
←
Previous Page
1
2